You are here:
PRE-NATAL EXPOSURES OF CHILDREN TO POLYBROMINATED DIPHENYL ETHERS: THE COLLECTION OF ANIMAL AND HUMAN DATA ALONG WITH THE DEVELOPMENT AND VALIDATION OF A PBPK MODEL
Description:
Little is known about in-utero exposures to most environmental chemicals, including the polybrominated diphenyl ethers (PBDEs). These PBDEs are known to have neurological effects and are suspected of having endocrine disruption capability. Work proposed in this study will lead to a physiologically-based pharmacokinetic (PBPK) model for PBDEs in an animal model system (rats).
Objective:The overall objectives are: 1. Develop a Physiologically Based Pharmacokinetic Model (PBPK) animal model for the Polybrominateddiphenyl ethers (PBDEs) 2,2',4,4'-tetrabromomodiphenyl ether and 2,2',4,4',5-pentabromodiphenyl ether (PBDEs) that can be used to estimate fetal exposures to PBDEs in humans. The parameters necessary to develop the model for PBDEs will be measured. 2. Analytical methods for PBDEs in human blood and meconium will be developed/installed and applied to samples collected during this project both to estimate the utility of the model and to determine if chemical analysis of cord blood and meconium are appropriate media for measurement of cumulative exposures of newborn babies to PBDEs. Specific hypotheses include: 1. A rodent PBPK model for PBDEs can be scaled to be applicable to humans. 2. The PBDE concentrations in cord blood and meconium from newborns are proportional. 3. Mother's blood concentrations of PBDEs are predictive of the cord blood and/or meconium concentrations in newborn babies. 4. Meconium is a useful medium for assessing cumulative dose of the developing fetus.
URLs/Downloads:
Final Progress Report2004 Progress Report
2005 Progress Report
URL
2003 Progress Report